S&P Futures
4,038.00 +2.25 (+0.06%) Dow Futures
32,771.00 -3.00 (-0.01%) Nasdaq Futures
12,877.00 +9.75 (+0.08%) Russell 2000 Futures
1,796.50 +3.20 (+0.18%) Crude Oil
69.50 +0.17 (+0.25%) Gold
1,941.50 +0.40 (+0.02%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.5131 |
| Open | 0.5000 |
| Bid | 0.0000 x 2200 |
| Ask | 0.0000 x 1800 |
| Day's Range | 0.4976 - 0.5220 |
| 52 Week Range | 0.4976 - 6.9000 |
| Volume | |
| Avg. Volume | 404,676 |
| Market Cap | 9.798M |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1730 |
| Earnings Date | May 09, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.38 |
- GlobeNewswire
PolyPid to Present at the Barclays Global Healthcare Conference
PETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023. Barclays Global Investor Conference: Presentation Date: Tuesday, March 14, 2023Presentation Time:4:35 PM Eastern Time Investors interested in meeting with PolyPid during th
- Insider Monkey
PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript February 8, 2023 Operator: Greetings, and welcome to the PolyPid Fourth Quarter and Full Year 2022 Conference Call. . As a reminder, this call is recorded. And I would now like to introduce your host for today’s conference, Brian Ritchie from LifeSci Advisors. Mr. Ritchie, you may […]
- GlobeNewswire
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient Recruitment in Q2 2023 into Ongoing SHIELD II Trial, which will be Enriched with Approximately 550 Additional Patients to Complete Clinical Testing for Potential NDA Top-line Results from SHIELD II Trial Anticipated mid-2024 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 08, 2023 (
